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Abstract
Background: Mannitol and hypertonic saline are used to ameliorate brain edema and intracranial hypertension
during and after craniotomy. We hypothesized that the agreement of measured and calculated serum osmolality
during the infusion of hypertonic saline would be better than mannitol. The objective was to determine the
accuracy of serum osmolality estimation by different formulas during the administration of hyperosmolar agent.
Methods: A prospective, randomized, double-blinded, controlled trial was conducted in a 30-bed neurosurgical
intensive care unit at a university hospital. Thirty-five adult patients requiring the use of hyperosmolar agents for
prevention or treatment of brain edema after elective craniotomy were enrolled, and randomly assigned 1:1 to
receive 125 mL of either 20 % mannitol (mannitol group) or 3.1 % sodium chloride solution (hypertonic saline
group) in 15 min. Serum osmolality, serum sodium and potassium concentration, blood urea nitrogen and blood
glucose concentration were measured during the study period. The primary outcome was the agreement of
measured and estimated serum osmolality during the infusion of the two experimental agents. We used Bland and
Altman’s limits of agreement analysis to clarify the accuracy of estimated serum osmolality. Bias and upper and
lower limits of agreement of bias were calculated.
Results: For each formula, the bias was statistically lower in hypertonic saline group than mannitol group (p < 0.001).
Within group comparison showed that the lowest bias (6.0 [limits of agreement: −18.2 to 30.2] and 0.8 [−12.9 to 14.5]
mOsml/kg in mannitol group and hypertonic saline group, respectively) was derived from the formula ‘2 × ([serum
sodium] + [serum potassium]) + [blood urea nitrogen] + [blood glucose]’.
Conclusions: Compared to mannitol, a better agreement between measured and estimated serum osmolality was
found during the infusion of hypertonic saline. This result indicates that, if hypertonic saline is chosen to prevent
or treat brain edema, calculated serum osmolality can be used as a reliable surrogate for osmolality measurement.
Trial registration: ClinicalTrials.gov identifier: NCT02037815
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Background
Brain edema and elevated intracranial pressure (ICP) are
potentially devastating complications following various
types of intracranial operations [1–3], and appropriate
treatments improve cerebral perfusion and reduce dam-
age by local compression of brain tissue [4, 5]. Hyperos-
molar agents have been used to ameliorate brain edema
and intracranial hypertension during and after craniot-
omy, where mannitol and hypertonic saline (HS) are the
two most extensively studied and most frequently used
in the clinical practice [6–12]. Although recent meta-
analyses suggested that HS might be more effective than
mannitol in controlling intracranial hypertension, no sig-
nificant differences have been found in neurological out-
come and side effects between the two agents [13–16].
The primary mechanism of hyperosmolar agents to
control brain edema is based on the increased osmotic
gradient across blood–brain barrier during drug infu-
sion, and this helps in the removal of water from brain
tissue to the intravascular space [17]. Clinical studies
showed that an osmotic gradient between blood and
brain of just above 10 mOsmol/kg was effective in redu-
cing ICP [18]. In clinical practice, serum osmolality can
be used as a surrogate measure of the effect of hyperos-
molar agents, with either mannitol or HS. The initial
target of serum osmolality is often set slightly above the
upper limit of normal range [10]. Acute renal failure
might develop when serum osmolality exceeds 320 mOs-
mol/kg during mannitol infusion [19]. Therefore, meas-
urement of serum osmolality during hyperosmolar agent
infusion is of clinical importance to determine clinical
efficacy, adjust dosage and avoid side effects.
Serum osmolality is often measured in laboratory by
cryoscopic technique as the reference method [20].
However, in clinical setting, routine measurement of
serum osmolality is not always feasible at bedside, either
in intensive care unit (ICU) or in the neurosurgical
ward. In this situation, clinicians usually estimate serum
osmolality by using formulas derived from serum osmoles
that can be measured by bedside blood gas analysis or
routine laboratory chemical analysis, such as serum so-
dium, potassium, urea, and glucose [21]. However, several
studies have shown that during mannitol infusion, calcu-
lated serum osmolality may lead to a systematic bias
compared to direct measurement [22–24]. This poor
agreement of measured and calculated osmolality during
mannitol infusion might be due to the osmolal gap, which
is the difference between the two values. Up to now, few
studies have been carried out to determine the accuracy of
serum osmolality estimation during HS infusion [23]. In
the present study, mannitol or HS was used in patients
after elective craniotomy, and serum osmolality was mea-
sured during drug infusion. Four most cited formulas
were chosen to estimate the serum osmolality [21].
Parameters in these formulas are easily collected in clin-
ical practice. The aim was to determine the accuracy of
serum osmolality estimation during the application of
hyperosmolar agents. We hypothesized that the agree-
ment of measured and calculated serum osmolality during
the infusion of HS would be better than mannitol.
Methods
IRB/Consent
The trial complied with the latest Declaration of
Helsinki. The study protocol was approved by the Insti-
tutional Review Board (IRB) of Beijing Tiantan Hospital,
Capital Medical University (KY-2013-002-003). Patients’
conscious state was impaired after surgery; therefore, we
obtained written consent from patients’ relatives.
Clinical Trial Registration
The study was registered on January 16, 2014 at the
ClinicalTrials.org (NCT02037815). The study protocol
was published in April, 2014 [25]. There were two major
changes in data analysis. First, the primary outcome was
changed from the correlation of measured and estimated
serum osmolality to the agreement of these two parame-
ters. Second, the limits of agreement analysis was chan-
ged to Bland-Altman method for repeated data.
Study design, setting and participants
We conducted a prospective, randomized, double-blinded,
controlled, parallel-group trial in the neurosurgical ICU
(30-bed), Beijing Tiantan Hospital (1100-bed), Capital
Medical University, Beijing, China, from January to May
2014.
All patients after elective intracranial surgery admitted
to our ICU were screened daily for study eligibility.
Inclusion criteria were as follows:
Age between 18 and 65 years;
Within 24 h after operation;
Hyperosmolar agents were required for the prevention
or treatment of post-operative brain edema.
Exclusion criteria were:
History of diabetes;
History of alcohol abuse;
Herniation of brain;
Unstable hemodynamic condition: systolic blood
pressure (BP) less than 90 mmHg or need for
continuous infusion of vasopressor;
Presence of oliguric renal failure;
Serum sodium concentration below 130 mmol/L or
above 155 mmol/L;
Enrolled in another trial.
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Patients were enrolled only once unless they were dis-
charged from the hospital and were readmitted beyond
180 days of the first enrollment.
After randomization (computer generated random
digits table in sealed and numbered envelopes), enrolled
patients were assigned 1:1 to receive 125 mL of either 20
% mannitol (M group) or 3.1 % sodium chloride solution
(HS group). A pharmacist filled 125 mL 20 % mannitol
or 3.1 % sodium chloride solution into a sterile 250 mL
glass bottle. Patients and all study personnel except the
investigative pharmacist were blind to treatment assign-
ment. These concentrations and doses of hyperosmolar
agents were chosen according to our standard clinical
practice for the prevention and treatment of post-
operative brain edema in patients after craniotomy. Indi-
cations included intracranial ICP above 25 mmHg, brain
edema shown by CT, or poor neurological status consid-
ered due to brain edema and bulging of brain during
operation. In our institute, the ICP monitoring was per-
formed in patients with external ventricular drainage
(Medtronic Neurosurgery, Goleta, CA, USA). Hyperos-
molar agents were initiated in some cases because of
clinical decline or elevated ICP, but in many others they
were instituted based on CT results or empirically.
Data collection and trial intervention
At study entry, data on demography, body mass index,
history of illness, diagnoses of the patients, duration of
operation, and type and amount of hyperosmolar agents
used during 24 h before the study drug infusion were re-
corded. Acute Physiology and Chronic Health Evaluation
II score (APACHE II) was calculated. Venous blood
sample (3 mL) was obtained and concentrations of
serum glucose, triglyceride, cholesterase, albumin, globu-
lins, total serum protein and blood urea nitrogen (BUN)
were measured by standard central laboratory device.
The reasons for the use of experimental hyperosmolar
agents were also documented.
After enrollment of the patient, 125 ml of either 20 %
mannitol (M group) or 3.1 % sodium chloride solution
(HS group) was infused via central venous line in
15 min by using an infusion pump. Type of fluid intake,
cumulative fluid intake, urine output and fluid balance
(intake minus output) were documented immediately
before the infusion of study agents (T0), 15 min
(T15min), 30 min (T30min), 60 min (T60min), 120 min
(T120min), 240 min (T240min) and 360 min (T360min)
after the start of experimental agents’ infusion. At the
same time points, 3 mL arterial blood sample and
10 mL urine sample were collected. Serum and urine
osmolality were measured by means of freezing point
depression [20]. Blood values of sodium, potassium, and
glucosewere measured using an ICU bedside blood gas
analyzer. Urine specific gravity and concentration of
sodium were also measured by standard central labora-
tory devices.
Calculation of serum osmolality and osmolal gap
We used four formulas to estimate serum osmolality [21]
2 × [Na+](Formula 1)
2 × ([Na+] + [K+]) + BG + BUN (Formula 2)
2 × [Na+] + 0.9 × BG + 0.93 × BUN × 0.5 (Formula 3)
1.9 × ([Na+] + [K+]) + BG + BUN × 0.5 + 5 (Formula 4)
[Na+], serum sodium concentration (mmol/L); [K+],
serum potassium concentration (mmol/L); BG, blood
glucose concentration (mmol/L); BUN, blood urea nitro-
gen (mmol/L).
Osmolal gap was calculated as the difference between
the measured values and each of the estimated values by
different formulas shown above.
Outcome measures
The primary outcome was the agreement of measured
and estimated serum osmolality (osmolal gap) during
the infusion of hyperosmolar agent. The differences be-
tween the measured and each of the calculated values
from different formulas were compared. Other outcome
measures included changes in the following values dur-
ing the infusion of experimental agents: serum and urine
osmolality, serum and urine sodium concentration, urine
specific gravity and fluid balance variables.
Statistical analysis
Previous investigation showed that by using the formula
2 listed above, the peak serum osmolal gap during man-
nitol infusion was 25 mOsmol/kg in patients with brain
injury [22]. We hypothesized that the serum peak osmo-
lal gap would decrease to 15 mOsmol/kg during the
infusion of 3.1 % sodium chloride solution. Using the
Power and Sample Size Calculation program, we needed
to enroll 15 patients in each group to be able to reject
the null hypothesis that the mean peak serum osmolal
gap of the two experimental groups was equal with a
probability (power) of 0.8. The Type I error probability
with testing this null hypothesis was 0.05.
All analyses were according to the intention-to-
treat principle, that was, all randomized patients were
analysed in the groups to which they had been
originally allocated and were blinded to treatment
assignment.
Categorical variables were presented as numbers and
percentages and analyzed by the χ2 test. Continuous
variables were checked for normal distribution and pre-
sented as mean and SD or median and IQR as appropri-
ate. Comparison of continuous variables was performed
by using Student t test for normally distributed variables
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and the Mann–Whitney U test for non-normally distrib-
uted variables.
We used Bland and Altman’s [26] limits of agreement
analysis to clarify the accuracy of estimated serum osmo-
lality calculated by each of the four formulas listed
above. Bias was defined as the mean of the difference be-
tween measured and calculated values (measured minus
calculated). SD of the mean bias was calculated accord-
ing to the agreement between methods of measurement
with multiple observations per individual [27]. Upper
and lower limits of agreement were defined as bias ±
1.96 SD of the mean bias.
We used repeated measures of analysis of variance for
comparing serum osmolal gap, serum and urine osmo-
lality, serum and urine sodium concentration, urine
specific gravity and fluid balance variables across differ-
ent time points (T0 to T360min) between the two
groups (M and HS groups).
All tests of significance were at 0.05. Analyses were
conducted using SPSS V.17.0.
Results
Between January and May 2014, 613 patients after elect-
ive intracranial surgery were admitted to the ICU and
screened for study eligibility. Hyperosmolar agents were
required in 187 patients for the prevention or treatment
of post-operative brain edema. Among these patients, 35
were enrolled and randomly assigned to M group or HS
group. Figure 1 shows the flow chart of patient
Fig. 1 The flow chart of patient participation
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participation. All patients completed the study interven-
tion and data analysis.
The enrolled patients comprised 18 males (51 %) and
17 females (49 %) with mean (±SD) age of 45 (±12)
years. All patients’ diagnoses were brain tumor. Baseline
characteristics are shown in Table 1.
Serum osmolality were measured 7 times in each pa-
tient, from immediately before (T0) to 360 min
(T360min) after the start of experimental agentsinfusion.
At the same time points, blood concentrations of so-
dium, potassium, and glucose were also measured. Blood
concentration of BUN was only measured at T0. Four
formulas were used to calculate serum osmolality. So,
245 paired data sets (126 in M group and 119 in HS
group) were obtained, which comprised measured and
four estimated serum osmolality. Table 2 shows the re-
sults of Bland and Altman’s limits of agreement analysis.
For each formula, bias was statistically lower in HS
group than in M group (p < 0.001). Within group com-
parison showed that, either in M group or in HS group,
there was significant difference in bias across any of the
four formulas (p < 0.001). The lowest bias with narrowest
limits of agreement between the measured and estimated
serum osmolality was derived from the formula 2, with
6.0 (−18.2 to 30.2) and 0.8 (−12.9 to 14.5) mOsmol/kg in
M group and HS group, respectively (Table 2).
Table 3 shows variables of osmolality, electrolytes, and
fluid balance during the infusion of experimental agents.
After the infusion of hyperosmolar agents, serum osmo-
lality increased statistically to the peak value (301.6 ±
10.5 [p < 0.001] and 299.6 ± 7.3 [p < 0.001] mOsmol/kg
in M group and HS group, respectively) at T15min in
both groups, and no significant differences were found
between the two groups at any time point (p = 0.515). In
M group, serum osmolality at T15min and T30min were
statistically higher than values at baseline and other time
points (p < 0.05), whereas values at T240min and
T360min decreased statistically below the baseline value
(p < 0.05). The change of serum osmolality in HS group
exhibited the same tendency as in M group. However, in
HS group, serum osmolality at T240min (p = 0.810) and
T360min (p = 0.076) were not statistically different from
baseline value.
Since serum osmolality was higher at T15min and
T30min in both M group and HS group, we combined
the data at this two time points to determine whether
desired serum osmolality was achieved. In M group, 4
(11.1 %) measurements were greater than 310 mOsmol/
kg, 3 (8.3 %) measurements were lower than 290 mOs-
mol/kg, while 27 (80.6 %) measurements were between
290 and 310 mOsmol/kg. In HS group, 4 (11.8 %) mea-
surements were greater than 310 mOsmol/kg while
other measurements were between 290 and 310 mOs-
mol/kg (Fig. 2).
Table 1 Baseline characteristics of the patients according to
randomization groups
Characteristics M group (n = 18) HS group (n = 17)
Age, years 44 ± 14 46 ± 10
Male 9 (50.0 %) 9 (52.9 %)
Body mass index 23.3 ± 4.7 24.5 ± 2.5
Operation time, h 5.1 ± 1.3 4.0 ± 1.0
Use of mannitol before the study
Incidence 4 (22 %) 5 (29 %)
Time of use before the study, h 10.3 ± 3.3 12.6 ± 3.3
Serum biochemistry
Sodium, mmol/L 137 ± 2 138 ± 3
Potassium, mmol/L 3.5 ± 0.3 3.5 ± 0.4
Glucose, mmol/L 6.66 ± 1.80 6.83 ± 1.64
Triglyceride, mmol/L 1.57 ± 0.27 1.64 ± 0.21
Cholesterase, mmol/L 4.21 ± 0.75 4.32 ± 1.02
Albumin, g/L 37.6 ± 3.4 36.8 ± 4.5
Globulins, g/L 24.8 ± 3.9 23.7 ± 3.2
Total protein, g/L 62.4 ± 6.6 60.5 ± 7.1
Blood urea nitrogen, mmol/L 3.9 ± 1.8 4.0 ± 1.2
APACHE II 15 ± 2 14 ± 3
Reason for use of hyperosmolar
agents
Treatment 5 (28 %) 5 (29 %)
Prevention 13 (72 %) 12 (71 %)
Data are presented as mean ± SD or number (%). APACHE II: Acute Physiology
and Chronic Health Evaluation II score
Table 2 Bland and Altman’s limits of agreement analysis
between measured and calculated serum osmolality (mOsmol/
kg) by the four formulas
Formulas M group (126 pairs) HS group (119 pairs)
Bias Limits of agreement Bias Limits of agreement
1 25.0 2.6 to 47.5 19.5 5.1 to 33.8
2 6.0 −18.2 to 30.2 0.8 −12.9 to 14.5
3 16.3 −7.5 to 40.2 11.3 −2.1 to 24.8
4 17.3 −6.2 to 40.7 12.6 −0.6 to 25.7
Data are presented as bias and lower to upper limits of agreement. The
differences between measured and calculated serum osmolality were
calculated in each data set. Bias was defined as the mean of difference
between the measured and calculated values. SD of the mean bias was
calculated according to the agreement between methods of measurement
with multiple observations per individual. Upper and lower limits of
agreement were defined as bias ± 1.96 SD
Patients in M group or HS group received 125 ml of either 20 % mannitol or
3.1 % sodium chloride solution, respectively
For each formula, the bias in HS group was statistically lower than in M group
(p < 0.001). Within group comparison showed that, either in M group or in HS
group, there was significant difference in bias between any of the two
formulas (p < 0.001)
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Table 3 Variables of osmolality, electrolytes, and fluid balance during the infusion of experimental agents
Variables Time M group HS group p value
Serum osmolality, mOsmol/kg T0 296.3 ± 11.2
bcfg 295.7 ± 7.4bcd 0.847
T15min 301.6 ± 10.5
acdefg 299.6 ± 7.3acdefg 0.515
T30min 298.9 ± 10.1
abdefg 298.4 ± 7.4abefg 0.875
T60min 297.0 ± 8.3
bcfg 297.8 ± 7.0abfg 0.770
T120min 296.7 ± 9.7
bcfg 296.6 ± 6.6bcg 0.963
T240min 294.9 ± 10.3
abcdeg 295.9 ± 6.5bcdg 0.751
T360min 292.4 ± 9.1
abcdef 294.1 ± 6.6bcdef 0.527
Serum osmolal gap*, mOsmol/kg T0 3.6 ± 12.1
bcgf 2.2 ± 6.9b 0.684
T15min 16.4 ± 11.4
acdefg −0.9 ± 6.2acd <0.001
T30min 10.8 ± 12.3
abdefg 2.0 ± 6.9b 0.014
T60min 5.3 ± 8.9
bcfg 1.3 ± 6.8b 0.142
T120min 3.7 ± 11.1
bcg 0.8 ± 7.2 0.368
T240min 2.4 ± 12.1
bcd −0.1 ± 8.1 0.470
T360min −0.1 ± 10.1
abcde 0.2 ± 6.5 0.905
Serum sodium, mmol/L T0 137.0 ± 2.1
bc 137.3 ± 2.8bcd 0.723
T15min 133.6 ± 2.6
acdefg 141.4 ± 3.1acdefg <0.001
T30min 134.9 ± 3.1
abdef 139.2 ± 3.5abg 0.001
T60min 136.6 ± 2.8
bc 139.1 ± 3.2abg 0.018
T120min 136.8 ± 3.4
bc 138.5 ± 3.7b 0.164
T240min 136.4 ± 3.2
bc 138.1 ± 3.3b 0.139
T360min 136.1 ± 3.5
b 137.5 ± 2.9bcd 0.202
Urine osmolality, mOsmol/kg T0 825.8 ± 92.1
bcde 824.2 ± 181.3bcdef 0.973
T15min 659.0 ± 123.0
aefg 727.4 ± 181.1a 0.198
T30min 638.1 ± 80.1
adefg 692.6 ± 186.2adfg 0.264
T60min 677.7 ± 79.0
acefg 731.1 ± 169.2ac 0.236
T120min 727.3 ± 84.9
abcdfg 719.3 ± 182.2a 0.868
T240min 788.5 ± 92.0
bcde 738.7 ± 209.3ac 0.354
T360min 808.9 ± 162.9
bcde 759.8 ± 224.3c 0.461
Urine sodium, mmol/L T0 199.2 ± 44.2
bcdefg 218.8 ± 63.3f 0.294
T15min 115.4 ± 30.6
af 210.5 ± 59.8f <0.001
T30min 106.7 ± 22.1
adfg 214.7 ± 44.4ef <0.001
T60min 116.6 ± 30.7
acf 214.6 ± 47.8ef <0.001
T120min 116.8 ± 36.5
af 199.1 ± 50.1cd <0.001
T240min 140.9 ± 33.5
abcde 184.7 ± 51.7abcd 0.005
T360min 137.4 ± 53.0
ac 195.1 ± 56.3d 0.004
Urine SG, kg/m3 T0 1.030 ± 0.007 1.028 ± 0.007
bcdefg 0.421
T15min 1.029 ± 0.006
e 1.023 ± 0.007a 0.007
T30min 1.029 ± 0.006
e 1.021 ± 0.007adef <0.001
T60min 1.031 ± 0.006 1.022 ± 0.006
ac <0.001
T120min 1.033 ± 0.006
bc 1.022 ± 0.006ac <0.001
T240min 1.032 ± 0.006 1.023 ± 0.007
ac <0.001
T360min 1.030 ± 0.009 1.023 ± 0.007
a 0.008
Cumulative fluid intake, mL T0 0 0 /
T15min 132 ± 16 131 ± 18 0.973
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Because the lowest bias between measured and esti-
mated serum osmolality was derived from the formula 2
(Table 2), serum osmolal gap was calculated according
to this formula. In M group, after the infusion of manni-
tol, osmolal gap increased statistically at T15min (16.4 ±
11.4 mOsmol/kg, p < 0.001) and T30min (10.8 ± 12.3
mOsmol/kg, p < 0.001), and decreased to the baseline
level at time points of T60min to T240min, then further
decreased statistically below the baseline value at
T360min (p = 0.002, Table 3). In HS group, the osmolal
gap at T15min (−0.9 ± 6.2 mOsmol/kg, p = 0.029) was
slightly but significantly lower than the baseline value
(Table 3). No significant differences were found among
values at baseline and at the time points from T30min to
T360min (p > 0.05). Between groups comparison showed
statistically higher osmolal gap at T15min (p < 0.001) and
T30min (p = 0.014) in M group than HS group, but no sig-
nificant differences existed at time points from T60min to
T360min (p > 0.05).
After the infusion of experimental agents, tendency of
change in serum sodium differed statistically between the
two groups (Table 3). In M group, after mannitol infusion,
serum sodium decreased statistically from 137.0 ±
2.1 mmol/L at baseline to 133.6 ± 2.6 mmol/L at T15min
(p < 0.001) and 134.9 ± 3.1 mmol/L at T30min (p = 0.001).
In HS group, serum sodium increased statistically from
137.3 ± 2.8 mmol/L at baseline to 141.4 ± 3.1 mmol/L at
T15min (p < 0.001), and maintained statistically greater
than baseline at T30min (p = 0.002) and T60min (p =
0.015).
The tendency of change in urine osmolality did not
differ between the two groups (Table 3). After the infu-
sion of study agents, urine osmolality decreased statisti-
cally at time points from T15min to T120min (p < 0.05),
and then recovered to baseline level. For urine sodium, sig-
nificant differences were found between the two groups at
all time points after the infusion of study agents (p < 0.05).
After the infusion of mannitol, urine sodium decreased sta-
tistically (p < 0.001). However, in HS group, urine sodium
did not change statistically (p > 0.05, only slightly decreased
at T240min [p = 0.007]). Significant difference was also
found in urine specific gravity after study agents’ infusion
between the two groups (p < 0.05). Urine specific gravity
in M group did not change statistically during the study
(p > 0.05), but in HS group, this parameter decreased sta-
tistically after infusion and remained in the level below
baseline (p < 0.05).
We also collected data of fluid balance during the
study period (Table 3). For cumulative fluid intake, there
was no significant difference between the two groups
Table 3 Variables of osmolality, electrolytes, and fluid balance during the infusion of experimental agents (Continued)
T30min 179 ± 23 187 ± 30 0.419
T60min 280 ± 84 257 ± 51 0.344
T120min 423 ± 102 381 ± 93 0.218
T240min 617 ± 144 647 ± 139 0.536
T360min 813 ± 186 855 ± 219 0.537
Cumulative urine output, mL T0 0 0 /
T15min 76 ± 45 49 ± 22 0.035
T30min 167 ± 66 94 ± 37 <0.001
T60min 300 ± 108 171 ± 71 <0.001
T120min 449 ± 155 303 ± 121 0.004
T240min 662 ± 183 537 ± 189 0.050
T360min 835 ± 221 775 ± 253 0.455
Cumulative fluid balance†, mL T0 0 0 /
T15min 56 ± 47 83 ± 28 0.051
T30min 12 ± 69 93 ± 49 <0.001
T60min −20 ± 139 86 ± 84 0.010
T120min −26 ± 179 79 ± 131 0.058
T240min −45 ± 233 110 ± 194 0.042
T360min −23 ± 267 81 ± 255 0.250
Data are presented as mean ± SD
Urine SG urine specific gravity
*: Calculated osmolality was derived from formula 2
†: Fluid balance = intake-output
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(p > 0.05). However, cumulative urine output in M group
was statistically higher than HS group, from T15min to
T240min (662 ± 183 mL in M group and 537 ± 189 mL
in HS group, p < 0.05). This resulted in the significant
differences in cumulative fluid balance between the two
groups. Cumulative fluid balance was statistically more
negative in M group than HS group at T30min, T60min
and T240min (p < 0.05).
Discussion
In this prospective, double-blinded, randomized con-
trolled trial, we determined the agreement of measured
and estimated serum osmolality during theoretically
equiosmolar load of mannitol and HS, and compared
the accuracy of serum osmolality estimation derived
from four common used formulas between the two
agents. The main findings of our study are that, (1)
calculation by using the formula ‘2 × ([Na+] + [K+]) +
BUN + BG’ provides the most accurate estimation of
serum osmolality after the infusion of HS; (2) an in-
crease of serum osmolality is observed after the infusion
of either 20 % mannitol or 3.1 % HS, and with the latter
this is associated with the increase in serum sodium
concentration; and (3) compared with HS, mannitol re-
sults in an abrupt and significant increase in osmolal gap
during the early stage after the infusion.
Hyperosmolar agents are frequently used in prevention
and treatment of brain edema during and after craniot-
omy and monitoring of serum osmolality is essential in
this situation [6–12]. A lot of formulas have been pub-
lished for the application of serum osmolality estimation in
general patients population [21]. Among these formulas,
several have been evaluated in neurological and neurosur-
gical patients during the administration of hyperosmolar
agents [22–24]. In these studies, different formulas were
used and different patients were enrolled (not treated with
hyperosmolar agents [24], treated with mannitol [22] or
treated with both mannitol and HS [23]). The results
showed a suboptimal correlation between measured and
calculated serum osmolality during mannitol administra-
tion [22, 23]. Although patients receiving mannitol and HS
were both enrolled in the study of Vialet et al., results of
mannitol and HS were not reported separately [23]. In
present study, we chose 4 most cited formulas [21], and
confirmed the most accurate formula for the estimation of
serum osmolality. Our results indicate that, if HS is chosen
to prevent or treat brain edema during post-operative
period, calculated serum osmolality can be used as a reli-
able surrogate for osmolality measurement.
In the present study, the theoretically equiosmolar
bolus of either mannitol or HS resulted in an abrupt
increase in serum osmolality, reaching the peak value by
the end of infusion (Table 3). This is consistent with the
results of previous studies [6, 7]. In Rozet et al. study,
5 ml/kg of 20 % mannitol and 3 % HS were administered
over 15 min, and both resulted in similar increase in
serum osmolality [6]. Francony et al. compared a single
infusion of either 231 mL of 20 % mannitol or 100 mL
of 7.45 % HS during 20 min of administration [7]. The
baseline serum osmolality was not significant different
between the two groups, with 296 ± 11 and 292 ± 13
mOsmol/kg in mannitol group and HS group, respect-
ively. Both agents caused 2 % increases in serum osmo-
lality at 30 min after the infusion, also with no
difference between the two groups. However, in our
study, we found that the magnitude of increase in
serum osmolality was higher, although not significantly,
after the infusion of 20 % mannitol than 3.1 % HS
(Table 3). Calculated osmolality of 20 % mannitol
(1098 mosmol/kg) and 3.1 % sodium chloride solution
(1054 mosmol/kg) are nearly equal, but measured
values are not. By means of freezing point depression,
we found that the real osmolality of 20 % mannitol and
3.1 % HS were about 1378 and 972 mOsmol/kg, re-
spectively. According to this result, 4.3 % HS (about
1341 mOsmol/kg) should be used to as the equal-
osmolar hyperosmolar agent with 20 % mannitol.
Fig. 2 Distribution of serum osmolality at T15min to T30min
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Up to now, only one study investigated osmolal gap
during HS infusion. Vialet et al. enrolled 20 patients
with traumatic brain injury, who received 2 mL/kg of
either 20 % mannitol (n = 10) or 7.5 % HS (n = 10) in
20 min [23]. By using the formula ‘2 × [Na+] + BUN +
BG’, they found an osmolal gap of −2.3 ± 7.2 mOsmol/kg
in this population, but unfortunately the respective value
in mannitol and HS group was not reported separately.
In our study, we calculated the osmolal gap by using the
formula ‘2 × ([Na+] + [K+]) + BUN + BG’, and found a dif-
ferent pattern of change in osmolal gap after the infu-
sion of mannitol and HS (Table 3). Osmolal gap
increased statistically at 15 to 30 min after the infusion
of mannitol, whereas remained almost unchanged after
the infusion of HS (slightly decreased at 15 min). The
increasing of serum osmolal gap after mannitol infusion
was mainly due to the inverse change of serum sodium
concentration after the infusion of the two agents. The
dynamic changes of serum sodium during the adminis-
tration of mannitol and HS in present study were com-
parable to previous reports [6–9, 28, 29]. The infusion of
mannitol attracts water from interstitial space to intra-
vascular space, which results in transient intravascular
volume expansion and dilutional hyponatremia.
In the present study, we also determined the influence
of hyperosmolar agents on fluid and urine variables
(Table 3). Since the cumulative fluid intake was not dif-
ferent between the two groups, higher cumulative urine
output after mannitol infusion resulted in a more nega-
tive fluid balance. This is in accordance with the effect
of osmotic diuresis with mannitol infusion reported in
previous studies [6–8, 30, 31]. These results suggest that
different strategy should be employed during mannitol
and HS therapy. Hypovolemia should be avoided after
mannitol infusion, whereas hypervolemia be avoided
after HS infusion.
There are some limitations to this study. First, although
it was not surprising that we found a lower osmolal gap
after the infusion of HS than mannitol, the most reliable
formulas for serum osmolality estimation was identified in
present study. Second, the doses of mannitol and HS
prepared and used in present study were not actually
equiosmolar. This is the same problem in other studies
for the comparison of equiosmolar hyperosmolar solu-
tions [6–8]. We found that 20 % mannitol (1378 mOs-
mol/kg) and 4.3 % HS (1341 mOsmol/kg) were measured
equiosmolar. Third, we only determined the change of
osmolality after single bolus of hyperosmolar agents. In
clinical practice, hyperosmolar agents are usually given
several times to maintain a hyperosmolar state. Our re-
sults cannot be applied to repeated use of hyperosmolar
agents. Fourth, we did not investigate the effect of hyper-
osmolar agents on intracranial pressure and other clinical
outcomes. However, this is beyond the scope of our study.
To our knowledge, this is the first prospective, rando-
mizedcontrolled, double-blinded human study compar-
ing the agreement of measured and estimated serum
osmolality during the infusion of mannitol and HS. The
results indicate that, if HS is chosen to prevent or treat
brain edema during post-operative period, calculated
serum osmolality can be used as a reliable surrogate for
osmolality measurement.
Conclusions
Compared to mannitol, a better agreement between
measured and estimated serum osmolality was found
during the infusion of hypertonic saline. This result indi-
cates that, if hypertonic saline is chosen to prevent or
treat brain edema, calculated serum osmolality can be
used as a reliable surrogate for osmolality measurement.
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